CA1077841A - Immunostimulating agent - Google Patents

Immunostimulating agent

Info

Publication number
CA1077841A
CA1077841A CA278,034A CA278034A CA1077841A CA 1077841 A CA1077841 A CA 1077841A CA 278034 A CA278034 A CA 278034A CA 1077841 A CA1077841 A CA 1077841A
Authority
CA
Canada
Prior art keywords
neuraminidase
agent
antigen
antigens
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA278,034A
Other languages
English (en)
French (fr)
Inventor
Friedrich R. Seiler
Jurgen Knop
Hans-Harald Sedlacek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Application granted granted Critical
Publication of CA1077841A publication Critical patent/CA1077841A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA278,034A 1976-05-11 1977-05-10 Immunostimulating agent Expired CA1077841A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2620649A DE2620649C3 (de) 1976-05-11 1976-05-11 Immunologisches Adjuvans

Publications (1)

Publication Number Publication Date
CA1077841A true CA1077841A (en) 1980-05-20

Family

ID=5977559

Family Applications (1)

Application Number Title Priority Date Filing Date
CA278,034A Expired CA1077841A (en) 1976-05-11 1977-05-10 Immunostimulating agent

Country Status (17)

Country Link
US (1) US4510129A (cg-RX-API-DMAC7.html)
JP (1) JPS52136914A (cg-RX-API-DMAC7.html)
AT (1) AT363590B (cg-RX-API-DMAC7.html)
AU (1) AU512240B2 (cg-RX-API-DMAC7.html)
BE (1) BE854512A (cg-RX-API-DMAC7.html)
CA (1) CA1077841A (cg-RX-API-DMAC7.html)
CH (1) CH630807A5 (cg-RX-API-DMAC7.html)
DE (1) DE2620649C3 (cg-RX-API-DMAC7.html)
DK (1) DK204277A (cg-RX-API-DMAC7.html)
FR (1) FR2350847A1 (cg-RX-API-DMAC7.html)
GB (1) GB1569003A (cg-RX-API-DMAC7.html)
IE (1) IE45145B1 (cg-RX-API-DMAC7.html)
IL (1) IL52048A (cg-RX-API-DMAC7.html)
IT (1) IT1075545B (cg-RX-API-DMAC7.html)
LU (1) LU77295A1 (cg-RX-API-DMAC7.html)
NL (1) NL7704998A (cg-RX-API-DMAC7.html)
NZ (1) NZ184039A (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI790483A7 (fi) * 1978-02-16 1979-08-17 Science Union & Cie Foerfarande foer framstaellning av ett enzym av bakteriellt ursprung och farmaceutiska kompositioner innehaollande detsamma
US4729893A (en) * 1984-12-26 1988-03-08 Robert L. Letcher Enteric encapsulation of ancrod for oral administration
GB9018061D0 (en) * 1990-08-17 1990-10-03 Wellcome Found Compositions for vaccines
US20030108927A1 (en) * 2000-04-03 2003-06-12 Kathryn Leishman Compositions and methods for the prevention, treatment and detection of tuberculosis and other diseases
US7078165B2 (en) * 2003-03-27 2006-07-18 Institut Pasteur Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof
GB0307989D0 (en) * 2003-04-07 2003-05-14 Mcewen Lab Ltd Therapeutic composition
AU2013323472B2 (en) * 2012-09-28 2018-07-05 Ellis KLINE Glycosidase regimen for treatment of infectious disease
JP7187024B2 (ja) 2016-07-01 2022-12-12 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 標的化された細胞表面編集のための複合体
EP3735458A4 (en) 2018-01-03 2022-04-27 Palleon Pharmaceuticals Inc. RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF

Also Published As

Publication number Publication date
ATA332577A (de) 1981-01-15
IL52048A0 (en) 1977-07-31
DE2620649B2 (de) 1980-03-13
AT363590B (de) 1981-08-10
AU2503377A (en) 1978-11-16
US4510129A (en) 1985-04-09
GB1569003A (en) 1980-06-11
IT1075545B (it) 1985-04-22
IE45145L (en) 1977-11-11
DK204277A (da) 1977-11-12
LU77295A1 (cg-RX-API-DMAC7.html) 1977-12-13
IE45145B1 (en) 1982-06-30
FR2350847B1 (cg-RX-API-DMAC7.html) 1980-02-29
NL7704998A (nl) 1977-11-15
DE2620649A1 (de) 1977-11-17
IL52048A (en) 1980-11-30
BE854512A (fr) 1977-11-14
AU512240B2 (en) 1980-10-02
JPS52136914A (en) 1977-11-16
FR2350847A1 (fr) 1977-12-09
JPS624371B2 (cg-RX-API-DMAC7.html) 1987-01-30
CH630807A5 (de) 1982-07-15
NZ184039A (en) 1980-04-28
DE2620649C3 (de) 1980-11-06

Similar Documents

Publication Publication Date Title
Klinman et al. DNA vaccines: safety and efficacy issues
Svehag et al. THE FORMATION AND PROPERTIES OF POLIOVIRUS-NEUTRALIZING ANTIBODY: II. 19S and 7S Antibody Formation: Differences in Antigen Dose Requirement for Sustained Synthesis, Anamnesis, and Sensitivity to X-Irradiation
US4185089A (en) Immunological adjuvant constituted by the p-amino-phenyl derivative of N-acetyl-muramyl-L-alanyl-D-isoglutamine
CA1077841A (en) Immunostimulating agent
Subba Rao et al. Immunosuppressive action of heat in chickens
US20250152685A1 (en) Method of making a personalized cancer vaccine
US9017699B2 (en) Adjuvancy and immune potentiating properties of natural products of Onchocerca volvulus
Ferguson et al. The immune response and the eye. II. The nature of T suppressor cell induction in anterior chamber-associated immune deviation (ACAID).
MX2007008013A (es) Metodos para producir, mejorar y sostener respuestas inmunes contra epitopos i-restringidos clase mhc por propositos profilacticos o terapeuticos.
Leung et al. Effect of helper T cells on the primary in vitro production of delayed-type hypersensitivity to influenza virus.
EA012066B1 (ru) Способ, вызывающий т-клеточный ответ
CA2606349C (en) Immunologically active compositions
Thorn Specific inhibition of cytotoxic memory cells produced against UV-induced tumors in UV-irradiated mice
Kanai et al. Induction and natural occurrence of serum nucleosomal DNA in autoimmune MRL/lpr/lpr mice: its relation to apoptosis in the thymus
EA009325B1 (ru) Противоопухолевая вакцина, способ получения противоопухолевой вакцины и способ проведения противоопухолевой иммунотерапии
IL30168A (en) Antigen-free vaccine and process for preparing it
Fleming et al. Sites of biosynthesis of immunoglobulins in guinea-pigs immunized with bacteriophage ΦX174
WO2004096244A1 (en) Method of preparing tumor vaccine for the inducement of anti-tumor activity and a pharmaceutical composition containing the same
Nakhanova et al. PREPARATION OF HYPERIMMUNE SERA FOR SARS-COV-2 VIRUS
Shinohara et al. Hapten-specific IgM and IgG antibody responses in mice against a thymus-independent antigen (DNP-Salmonella)
HARAN-GHERA Latent Period in leukaemia induction by the radiation leukaemia virus
Roska et al. Immune complex disease in guinea pig lungs: elicitation with pigeon serum
Gurvich et al. Induction of abundant antibody formation with a protein-cellulose complex in mice
RU2094057C1 (ru) Способ получения вакцины против лихорадки ку
Stylos et al. Rabbit thyroid autoantibody produced by intravenous injections of papain-treated rabbit thyroid extract

Legal Events

Date Code Title Description
MKEX Expiry